Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases.
ashmi Murthy1, Sherene Loi2, Alicia Okines3, Elisavet Paplomata4, Erika Hamilton5, Sara Hurvitz6, Nancy Lin7, Virginia Borges8, Vandana Gupta Abramson9, Carey Anders10, Philippe L Bedard11, Mafalda Oliveira12, Erik Jakobsen13, Thomas Bachelot14, Shlomit S Shachar15, Volkmar Mueller16, Sofia Braga17, Francois P Duhoux18, Richard Greil19, David Cameron20, Lisa Carey21, Giuseppe Curigliano22, Karen Gelmon23, Gabriel Hortobagyi1, Ian Krop7, Sibylle Loibl24, Mark Pegram25, Dennis Slamon6, Maria Corinna Palanca-Wessels26, Luke Walker26, Wentao Feng26 and Eric Winer
Comunicaciones en congresos
Oral presentation
SABCS
2019
HER2CLIMB
